Novo Nordisk spies great hemophilia opportunities with partner Genmab

Pharmaceutical firm Novo Nordisk is expecting to send a new hemophilia drug to the market in 2025. It might end up being one of the best, according to Novo exec Martin Holst Lange.
Martin Holst Lange, executive vice president of development at Novo Nordisk | Photo: Novo Nordisk / PR
Martin Holst Lange, executive vice president of development at Novo Nordisk | Photo: Novo Nordisk / PR
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen

Novo Nordisk’s lucrative biopharma arm has stopped hemorrhaging, but growth is still a way away following years of this being the status quo. The hemophilia treatment Mim8 could speed up this process.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading